Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in EUR (TTM)40.66m
- Net income in EUR-127.12m
- Incorporated2000
- Employees345.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttp://www.cellectis.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | 5.28m | -28.62m | 96.55m | 38.00 | -- | 6.08 | -- | 18.30 | -0.6338 | -0.6338 | 0.1186 | 0.3453 | 0.1015 | -- | 13.09 | 138,842.10 | -55.03 | -63.75 | -88.54 | -83.23 | -- | -- | -542.40 | -1,456.76 | -- | -15.63 | 0.5226 | -- | 20.07 | -- | 15.87 | -- | -29.91 | -- |
| Eurofins-Cerep SA | 41.62m | 9.84m | 102.90m | 197.00 | 10.45 | 2.27 | 9.21 | 2.47 | 1,951.38 | 1,951.38 | 8,257.30 | 9,003.02 | 0.7868 | 2.41 | 6.40 | 211,252.70 | 18.61 | 14.15 | 23.21 | 17.77 | 86.29 | 59.01 | 23.65 | 17.72 | 3.70 | 13.88 | 0.0623 | -- | 27.40 | 12.17 | 76.48 | 31.68 | -- | -- |
| Maat Pharma SA | 972.00k | -9.02m | 109.74m | 33.00 | -- | 2.75 | -- | 112.90 | -0.9103 | -0.9103 | 0.0983 | 4.03 | -- | -- | -- | 29,454.54 | -- | -- | -- | -- | 43.31 | -- | -927.88 | -- | 10.04 | -73.50 | 0.1272 | -- | -- | -- | -70.14 | -- | -- | -- |
| Ose Immunotherapeutics SA | 26.31m | -16.85m | 126.73m | 61.00 | -- | 2.64 | -- | 4.82 | -0.9309 | -0.9309 | 1.45 | 2.59 | 0.2646 | -- | 28.50 | 431,245.90 | -16.95 | -9.88 | -20.06 | -11.76 | -- | -- | -64.05 | -45.90 | -- | -20.47 | 0.4367 | -- | 152.17 | 133.01 | -1.78 | -- | 73.53 | -- |
| Pcas SA | 187.01m | -40.48m | 132.04m | 1.17k | -- | 4.31 | -- | 0.706 | -2.95 | -2.95 | 13.61 | 2.02 | 0.6366 | 1.72 | 9.23 | 159,701.10 | -13.78 | -4.98 | -32.54 | -8.49 | 34.65 | 41.29 | -21.64 | -6.53 | 0.314 | -12.55 | 0.7172 | -- | -3.66 | -0.5247 | -170.81 | -- | 12.84 | -- |
| Biocorp Production SA | 10.23m | 294.23k | 139.59m | 67.00 | 473.16 | -- | -- | 13.65 | 0.0676 | 0.0676 | 2.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 95.91 | 93.83 | 2.88 | -38.40 | -- | 1.53 | -- | -- | 20.92 | 28.22 | 123.68 | -- | -- | -- |
| Medincell SA | 8.56m | -20.02m | 147.34m | 150.00 | -- | -- | -- | 17.21 | -0.8369 | -0.8369 | 0.3599 | -0.0655 | 0.1782 | -- | 17.95 | 57,858.11 | -41.67 | -- | -55.20 | -- | 83.23 | -- | -233.84 | -- | 2.84 | -15.03 | 1.04 | -- | 187.03 | -- | 20.47 | -- | -- | -- |
| Groupe Berkem SA | -100.00bn | -100.00bn | 155.45m | 164.00 | -- | 5,185.17 | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.05 | -- | 0.5806 | -- | 13.54 | -- | -62.94 | -- | -- | -- |
| Cellectis SA | 40.66m | -127.12m | 161.38m | 345.00 | -- | 0.8922 | -- | 3.97 | -2.81 | -2.81 | 0.9006 | 3.98 | 0.1087 | -- | 3.04 | 117,855.20 | -36.59 | -24.90 | -44.41 | -30.71 | -- | -29.56 | -336.58 | -232.72 | -- | -- | 0.3221 | -- | -18.66 | 3.51 | -40.86 | -- | -18.03 | -- |
| DBV Technologies SA | 5.41m | -92.85m | 165.47m | 226.00 | -- | -- | -- | 30.61 | -1.70 | -1.70 | 0.0987 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,717.80 | -1,272.93 | -- | -586.89 | -- | -- | -49.38 | -10.69 | 38.59 | -- | -- | -- |
| Genfit SA | 85.58m | 67.26m | 168.97m | 122.00 | 3.17 | 1.42 | 2.41 | 1.97 | 1.07 | 1.07 | 1.54 | 2.39 | 0.3563 | 367.75 | 21.32 | -- | 28.01 | -18.67 | 34.81 | -21.82 | 98.28 | 93.39 | 78.59 | -157.66 | 4.27 | -- | 0.3735 | -- | 1,003.11 | 66.03 | 166.45 | -- | -23.40 | -- |
| Biosynex SA | 153.90m | 31.37m | 176.81m | 200.00 | 5.68 | 2.39 | 5.38 | 1.15 | 3.05 | 3.05 | 16.81 | 7.24 | 1.78 | 4.19 | 21.50 | 769,476.90 | 37.23 | 13.99 | 54.80 | 18.12 | 45.04 | 48.57 | 20.94 | 12.31 | 1.12 | -- | 0.1922 | 5.51 | 349.59 | 73.21 | 2,711.82 | -- | -- | -- |
| Nanobiotix SA | 10.00k | -47.00m | 179.01m | 100.00 | -- | 6.68 | -- | 17,900.50 | -1.35 | -1.35 | 0.0003 | 0.7696 | 0.00008 | -- | 0.3226 | 100.00 | -39.87 | -52.22 | -52.25 | -66.48 | -- | -- | -470,040.00 | -37,902.42 | -- | -- | 0.6159 | -- | -80.00 | -63.57 | -39.93 | -- | -- | -- |
| Eurobio Scientific SA | 222.34m | 80.86m | 224.14m | 168.00 | 2.77 | 1.68 | 2.54 | 1.01 | 7.14 | 7.14 | 19.39 | 11.74 | 1.49 | 6.47 | 5.83 | -- | 54.30 | -- | 70.99 | -- | 60.58 | 50.51 | 36.37 | 23.24 | 4.18 | 97.93 | 0.1183 | -- | -2.20 | 46.13 | -17.67 | -- | -- | -- |
| Innate Pharma SA | 12.11m | -45.48m | 231.76m | 215.00 | -- | 2.15 | -- | 19.14 | -0.572 | -0.6634 | 0.1523 | 1.35 | 0.0421 | -- | 2.12 | 56,334.88 | -15.82 | -6.65 | -20.23 | -9.58 | 74.69 | 92.81 | -375.48 | -45.00 | -- | -- | 0.4407 | -- | -78.43 | -26.42 | -5,385.89 | -- | -32.35 | -- |
| Transgene SA | 17.01m | -19.54m | 232.94m | 167.00 | -- | 3.40 | -- | 13.69 | -0.219 | -0.219 | 0.1867 | 0.6874 | 0.1817 | -- | 2.88 | 101,880.20 | -20.86 | -15.27 | -24.56 | -18.27 | -- | -- | -114.82 | -147.28 | -- | -- | 0.0541 | -- | 82.10 | 14.28 | -13.38 | -- | 90.14 | -- |
Data as of May 23 2022. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR
14.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 31 Dec 2021 | 3.26m | 7.16% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2022 | 1.08m | 2.37% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2021 | 581.75k | 1.28% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 519.00k | 1.14% |
| BlackRock Fund Advisorsas of 04 May 2022 | 417.56k | 0.92% |
| Bessemer Investment Management LLCas of 31 Jan 2022 | 389.06k | 0.86% |
| KBC Fund Management Ltd.as of 31 Dec 2021 | 163.45k | 0.36% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Nov 2021 | 160.13k | 0.35% |
| Financi�re Arbevel SAas of 30 Jun 2021 | 110.00k | 0.24% |
| Saint Olive Gestion SNCas of 31 Jan 2021 | 85.00k | 0.19% |
More ▼
Data from 31 Jan 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
